Forest Oil Corporation (NYSE:FST) up by 5.44%, MannKind Corporation (NASDAQ:MNKD)

Posted by Chris Bell May 5, 2013 0 Comment 1645 views


Forest Oil Corporation (NYSE:FST): In Friday’s trading session there was a reasonable rise of 5.44 % in Forest Oil Corporation (NYSE:FST) shares. The opening price of the shares was 44.31 which touched an intraday high of $4.59 before settling down to $4.26 per share. Over 5.11M shares were traded in Friday’s trading session which was fairly higher than the average volume of 4.30 M that was measured over the last 30 days.

Forest Oil Corporation (NYSE:FST) has recently sealed a deal with the Eagle Ford and Schlumberger joint venture. Some market watchers are expecting this deal to boost FST further. Though the oil and gas market has had its up’s and down’s over the past years, a large part of the world relies largely on fossil fuels for their energy requirements. As of Dec 2011, it is estimated that Forest Oil has 1,904 billion in cubic feet equivalents and 97 percent of its total reserves are located in the United States.

Forest Oil Corporation (NYSE:FST) is an independent entity that operates in the oil and gas sector. It is involved in acquiring, exploring, developing and producing natural gas, oil as well as natural gas liquids in the North American region.

MannKind Corporation (NASDAQ:MNKD): In Friday’s trading session there was a dip of 2.24% in MannKind Corporation (NASDAQ:MNKD) shares. The opening price of the shares was $4.06 which touched an intraday high of $4.12 before dropping to $3.91 per share. Over 4.53M shares were traded in Friday’s trading session which was lower than the average volume of 4.95M that was measured over the last 30 days.

MannKind Corporation (NASDAQ:MNKD) is focused on the invention, development as well as the commercialization of various therapeutic products that are used by patients who suffer from chronic diseases such as diabetes. Its marquee product AFREZZA is currently in a late-stage clinical study is used in adult diabetes type 1 or 2 treatment. This medication also called insulin human is in a powder form that has to be inhaled by the patient and uses the Technosphere formulation technology. In addition to this the company is also involved in the development of cancer-drugs and treatments.


About Chris Bell

Chris Bell is an investing reporter for GDP Insider. Chris covers financial markets and Wall Street, concentrating on developments affecting individual investors and their portfolios. Chris is also over consumer reporter and covers a wide variety of issues ranging from housing to immigration to urban poverty. Chris graduated from the University of Scranton with a degree in Communication and Philosophy. Chris's diligent investigations earned him the honor of being named "Best Reporter" once by the Headliners Foundation of Texas and once by the Houston Press Club.

View all post by Chris Bell Visit author's website

Write Your Comment